Developing comprehensive screening for early-stage cancer is the key to saving the most lives.
Although multi-cancer early detection (MCED) tests are still being researched and lack FDA approval, several are commercially available for consumers who are willing to pay out-of-pocket. Individuals can ask their doctor to order the rel=”nofollow” href=”https://www.galleri.com/hcp?utm_source=google&utm_medium=cpc&utm_term=grail-cancer-test&utm_content=hcp-brand&utm_campaign=galleri-hcp-brand&trafficsheetid=t130603&gclsrc=aw.ds&gad_source=1&gad_campaignid=21362545643&gbraid=0AAAAABZLkwaFM39LU4PYvLKEh5eBFDn8r&gclid=CjwKCAjwup3HBhAAEiwA7euZuux9AbPa0VjYaFC_i-5GK0woDWDIaPzW5AmcrX37vMu3AAVfvngkQhoCDxsQAvD_BwE”>Galleri blood test from Grail, or they can opt for a whole-body MRI from companies like Prenuvo or Ezra, which often cost $2,000 or more.
Soon, consumers will have another — and rather unique—way to screen for…
